Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Zenas BioPharma has a “Moderate Buy” consensus rating from nine analysts: six buys, two holds and one sell. The average 12-month price target is $45.71, compared with the stock’s recent opening price of $32.29.
• The company reported disappointing quarterly results, posting an EPS loss of $1.77 versus the expected $1.12 loss and revenue of $1 million versus the $15 million consensus estimate. Analysts forecast a full-year loss of $5.81 per share.
• Institutional interest increased during the second quarter, with Wellington Management raising its stake by 27.9%, UBS Asset Management increasing holdings by 143.4% and Bank of America establishing a new position worth approximately $31.2 million.

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $45.7143.

Several analysts have commented on ZBIO shares. Morgan Stanley raised their price objective on Zenas BioPharma from $22.00 to $32.00 and gave the company an "equal weight" rating in a report on Friday, August 14th. Zacks Research upgraded shares of Zenas BioPharma from a "strong sell" rating to a "hold" rating in a research report on Friday, May 15th. Wall Street Zen raised shares of Zenas BioPharma from a "strong sell" rating to a "sell" rating in a report on Saturday, June 27th. Wedbush reiterated an "outperform" rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Friday, August 14th. Finally, Weiss Ratings cut shares of Zenas BioPharma from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, July 9th.

Zenas BioPharma Trading Up 2.1%

ZBIO stock opened at $32.29 on Friday. Zenas BioPharma has a 52-week low of $13.50 and a 52-week high of $44.60. The company has a quick ratio of 9.93, a current ratio of 9.93 and a debt-to-equity ratio of 1.57. The firm has a market cap of $2.10 billion, a P/E ratio of -3.59 and a beta of -1.03. The company's 50-day simple moving average is $28.27 and its 200-day simple moving average is $23.78.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to analysts' expectations of $15.00 million. As a group, equities analysts forecast that Zenas BioPharma will post -5.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Zenas BioPharma by 143.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 37,790 shares of the company's stock valued at $959,000 after acquiring an additional 22,267 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Zenas BioPharma by 27.9% in the second quarter. Wellington Management Group LLP now owns 1,593,819 shares of the company's stock worth $40,451,000 after acquiring an additional 347,766 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Zenas BioPharma during the second quarter worth approximately $31,247,000. Jupiter Topco LLC purchased a new stake in shares of Zenas BioPharma during the second quarter worth approximately $201,000. Finally, J. Goldman & Co LP acquired a new position in Zenas BioPharma in the 2nd quarter valued at $1,732,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source